Cite
APA Citation
Robson, M. E., Tung, N., Conte, P., Im, S. -., Senkus, E., Xu, B., Masuda, N., Delaloge, S., Li, W., Armstrong, A., Wu, W., Goessl, C., Runswick, S., & Domchek, S. M. (2019). olympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of oncology, 30, 558–566. http://access.bl.uk/ark:/81055/vdc_100094073912.0x000039